These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 37958317)
1. PD-1/PD-L1 Inhibitors plus Chemotherapy Versus Chemotherapy Alone for Resectable Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Pasqualotto E; Moraes FCA; Chavez MP; Souza MEC; Rodrigues ALSO; Ferreira ROM; Lopes LM; Almeida AM; Fernandes MR; Santos NPCD Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958317 [No Abstract] [Full Text] [Related]
2. Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC: An Indirect Meta-Analysis. Zhou Y; Li A; Yu H; Wang Y; Zhang X; Qiu H; Du W; Luo L; Fu S; Zhang L; Hong S JAMA Netw Open; 2024 Mar; 7(3):e241285. PubMed ID: 38451524 [TBL] [Abstract][Full Text] [Related]
3. Is neoadjuvant immunotherapy necessary in patients with programmed death ligand 1 expression-negative resectable non-small cell lung cancer? A systematic review and meta-analysis. Zhang SL; Tian Y; Yu J; Zhang JH; Sun L; Huang LT; Ma JT; Han CB Lung Cancer; 2024 May; 191():107799. PubMed ID: 38669725 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of perioperative, neoadjuvant, or adjuvant immunotherapy alone or in combination with chemotherapy in early-stage non-small cell lung cancer: a systematic review and meta-analysis of randomized clinical trials. Meng Y; Zhang Q; Wu R; Li H; Wang Z; Yao Y; Li X; Chen Z; Gong Y; Liu H Ther Adv Med Oncol; 2024; 16():17588359241284929. PubMed ID: 39376583 [TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis. Xin Y; Shen G; Zheng Y; Guan Y; Huo X; Li J; Ren D; Zhao F; Liu Z; Li Z; Zhao J BMC Cancer; 2021 Nov; 21(1):1261. PubMed ID: 34814874 [TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of neoadjuvant immunochemotherapy in resectable stage I-III non-small cell lung cancer: a systematic review and network meta-analysis. Li B; Gu Y; Zhao W; Li Z; Guo W; Lu X; Jiang J Clin Transl Oncol; 2024 Sep; ():. PubMed ID: 39251495 [TBL] [Abstract][Full Text] [Related]
8. Treatment-related Adverse Events, Including Fatal Toxicities, in Patients With Extensive-stage Small-cell Lung Cancer Receiving Adjuvant Programmed Cell Death 1/Programmed Cell Death Ligand 1 Inhibitors: A Meta-analysis and Trial Sequential Analysis of Randomized Controlled Trials. Moraes FCA; Lôbo AOM; Sano VKT; Kelly FA; Burbano RMR Clin Oncol (R Coll Radiol); 2024 Oct; 36(10):e408-e419. PubMed ID: 39079829 [TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials. Li ZQ; Yan HC; Gu JJ; Yang YL; Zhang MK; Fang XJ Pharmacol Res; 2020 Oct; 160():105194. PubMed ID: 32937178 [TBL] [Abstract][Full Text] [Related]
10. Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis. Conforti F; Pala L; Bagnardi V; Viale G; De Pas T; Pagan E; Pennacchioli E; Cocorocchio E; Ferrucci PF; De Marinis F; Gelber RD; Goldhirsch A J Natl Cancer Inst; 2019 Aug; 111(8):772-781. PubMed ID: 31106827 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of PD-1/PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis. Zhang M; Song J; Yang H; Jin F; Zheng A Acta Oncol; 2022 Sep; 61(9):1105-1115. PubMed ID: 35939538 [TBL] [Abstract][Full Text] [Related]
12. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis. Ba H; Liu L; Peng Q; Chen J; Zhu YD BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004 [TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials. Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis. Li Y; Liang X; Li H; Chen X Chin Med J (Engl); 2023 Sep; 136(18):2156-2165. PubMed ID: 37596898 [TBL] [Abstract][Full Text] [Related]
15. Short-term outcome of neoadjuvant immunotherapy and chemotherapy in non-small cell lung cancer: A systematic review and meta-analysis. Zhang C; Hong HZ; Wu YL; Zhong WZ JTCVS Open; 2021 Dec; 8():588-607. PubMed ID: 36004199 [TBL] [Abstract][Full Text] [Related]
16. Effectivity and safety of PD-1/PD-L1 inhibitors for different level of PD-L1-positive, advanced NSCLC: A meta-analysis of 4939 patients from randomized controlled trials. Shi Y; Duan J; Guan Q; Xue P; Zheng Y Int Immunopharmacol; 2020 Jul; 84():106452. PubMed ID: 32339922 [TBL] [Abstract][Full Text] [Related]
17. PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer: a systematic review and meta-analysis of randomized clinical trials. de Moraes FCA; Pasqualotto E; Lopes LM; Cavalcanti Souza ME; de Oliveira Rodrigues ALS; de Almeida AM; Stecca C; Fernandes MR; Dos Santos NPC BMC Cancer; 2023 Nov; 23(1):1166. PubMed ID: 38031003 [TBL] [Abstract][Full Text] [Related]
18. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993 [TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant immunotherapy for advanced, resectable non-small cell lung cancer: A systematic review and meta-analysis. Wu Y; Verma V; Gay CM; Chen Y; Liang F; Lin Q; Wang J; Zhang W; Hui Z; Zhao M; Wang J; Chang JY Cancer; 2023 Jul; 129(13):1969-1985. PubMed ID: 36994945 [TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis. Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]